A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Unadjuvanted RSV Maternal Vaccine Compared to Placebo When Administered to Healthy Non-pregnant Women.
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs GSK-3888550A (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Acronyms RSV MAT-001
- Sponsors GlaxoSmithKline
- 03 Oct 2019 Status changed from active, no longer recruiting to completed.
- 17 May 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Mar 2019 Planned End Date changed from 19 Sep 2019 to 17 Sep 2019.